Joint Initiative in Vaccine Economics (JIVE) Project

疫苗经济学联合倡议 (JIVE) 项目

• 批准号: 6902964
• 负责人: Tracy A Lieu
• 金额: $ 39.97万
• 依托单位: HARVARD PILGRIM HEALTH CARE, INC.
• 依托单位国家: 美国
• 财政年份: 2004
• 资助国家: 美国
• 起止时间: 2004-09-30 至 2007-09-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6902964
• 关键词: Herpesviridae vaccine; adult human (21+); clinical research; cooperative study; cost effectiveness; health care policy; health economics; human subject; influenza vaccines; interview; longitudinal human study; pain; shingles; vaccine evaluation

DESCRIPTION (provided by applicant): Background. As the nation's dominant purchaser of vaccines and supporter of immunization services, the Centers for Disease Control and Prevention have an ongoing need for objective economic information about new vaccines and vaccine programs. Specific Aims. For the past 3 years, we have been conducting collaborative research in vaccine economics with CDC colleagues via the Joint Initiative in Vaccine Economics (JIVE) Project. We propose to continue this project, initiating 4 new studies during the coming 3 years. We will: 1. Conduct the Zoster Utilities Evaluation, a study of utilities (preferences) for health outcomes associated with adult zoster and varicella vaccination of adults. These utilities will provide key data for analyses of the benefit-risk tradeoffs and the cost-effectiveness of vaccinating adults against zoster. 2. Carry out an applied study in vaccine economics that addresses a top-priority question in global infectious disease policy; 3. Design and lead an economic study to inform policy decisions for influenza vaccination; 4. Conduct an economic study that addresses an emerging immunization services policy question. Methods and Study Design. For the Zoster Utilities Evaluation (Specific Aim 1), we will use a prospective cohort design and will conduct telephone interviews with two subgroups: (1) Recent-zoster patients - adults who have recently had zoster or post-herpetic neuralgia; and (2) Community representatives - adults selected at random from health plan populations. The study population will be identified using the computerized databases of Harvard Vanguard Medical Associates and Northern California Kaiser Permanente. We will administer a structured, closed-ended interview that includes standard gamble and/or time trade-off questions about utilities for health states associated with zoster and adult varicella vaccination, as well as important predictor variables. Statistical analyses will use nonparametric bivariate tests and multivariate models. We will test the hypothesis HI: Zoster-associated pain will be rated worse by patients who have recently experienced zoster than by adult community members. For Specific Aims 2, 3, and 4, we will select and develop the specific research questions in collaboration with CDC colleagues during the first three months of the timeline. We will choose methods appropriate for the research questions selected. Project Management and Collaborative Efforts. The investigators are uniquely qualified to conduct this work. This is a multidisciplinary team based at Harvard with advanced skills in decision analysis, a recommended method of evaluating the benefits, risks, and economic effects of health policies. The Harvard-based project leaders are Tracy Lieu, MD, MPH, a pediatrician and researcher with a decade of experience in vaccine economics; Kim Thompson, PhD, a risk and decision sciences researcher with experience in global infectious disease analyses; Lisa Prosser, PhD, a health economics researcher with advanced skills in utility assessment; and Grace Lee, MD, MPH, a pediatric infectious disease specialist with expertise in cost-effectiveness analysis. This team has been highly productive in current collaborations with CDC colleagues on the cost-effectiveness of vaccination policies for pertussis, influenza, polio, and hepatitis B. Anticipated Policy Impact. This research will provide key data to inform important vaccine policy decisions, including the question of whether to vaccinate adults against zoster. By continuing our collaborative work with CDC colleagues, we will address the long-term goals of enhancing the nation's capacity and methodology for answering important economic questions about vaccines and other health interventions.

描述（由申请人提供）： 背景作为美国主要的疫苗购买者和免疫服务的支持者，疾病控制和预防中心一直需要有关新疫苗和疫苗计划的客观经济信息。 具体目标。在过去的3年里，我们一直在通过疫苗经济学联合倡议（JIVE）项目与CDC同事进行疫苗经济学方面的合作研究。我们建议继续这个项目，在未来3年内启动4项新的研究。我们将： 1.进行带状疱疹效用评估，这是一项与成人带状疱疹和水痘疫苗接种相关的健康结果的效用（偏好）研究。这些实用程序将提供关键数据分析的利益-风险权衡和成本效益接种成人带状疱疹。 2.开展疫苗经济学应用研究，解决全球传染病政策中的一个最优先问题; 3.设计并领导一项经济研究，为流感疫苗接种政策决策提供信息; 4.进行一项经济研究，解决一个新出现的免疫服务政策问题。 方法和研究设计。对于带状疱疹效用评价（具体目标1），我们将采用前瞻性队列设计，并对两个亚组进行电话访谈：（1）近期带状疱疹患者-近期患有带状疱疹或疱疹后神经痛的成人;（2）社区代表-从健康计划人群中随机选择的成人。将使用哈佛Vanguard Medical Associates和北方加州Kaiser Permanente的计算机化数据库确定研究人群。我们将进行一次结构化的封闭式访谈，其中包括标准的赌博和/或时间权衡问题，这些问题涉及与带状疱疹和成人水痘疫苗接种相关的健康状况的效用，以及重要的预测变量。统计分析将使用非参数双变量检验和多变量模型。我们将检验假设HI：最近经历带状疱疹的患者的带状疱疹相关疼痛将比成年社区成员更严重。 对于具体目标2、3和4，我们将在时间轴的前三个月与CDC同事合作选择和开发具体的研究问题。我们将选择适合所选研究问题的方法。 项目管理和协作努力。调查员是唯一有资格开展这项工作的人。 这是一个多学科的团队，总部设在哈佛，拥有先进的决策分析技能，这是一种推荐的评估健康政策的收益，风险和经济影响的方法。哈佛大学的项目负责人是Tracy Lieu，医学博士，公共卫生硕士，儿科医生和研究员，在疫苗经济学方面有十年的经验; Kim Thompson，博士，风险和决策科学研究员，在全球传染病分析方面有经验;丽莎Prosser，博士，卫生经济学研究员，在效用评估方面有先进的技能; Grace Lee，医学博士，公共卫生硕士，儿科传染病专家，擅长成本效益分析。该团队目前与CDC同事就百日咳、流感、脊髓灰质炎和B型肝炎疫苗接种政策的成本效益进行了高效合作。 预期的政策影响。这项研究将提供关键数据，为重要的疫苗政策决策提供信息，包括是否为成年人接种带状疱疹疫苗的问题。通过继续与疾病预防控制中心的同事合作，我们将实现长期目标，即提高国家回答有关疫苗和其他卫生干预措施的重要经济问题的能力和方法。